Background Immune checkpoint inhibitors (ICIs) for treatment of non-small cell lung cancer
(NSCLC) have been rapidly evolving. ICIs are likely to be more effective but also lead to …

Metastatic cancer is a heterogeneous entity, some of which could benefit from local
consolidative radiation therapy (RT). Although randomized evidence is growing in support of …

Objective Results of Orient 15 indicated the health benefits to patients with local advanced
or metastatic oesophageal squamous cell carcinoma (OSCC). This study aimed to evaluate …

Objective Results of CameL-sq has revealed the clinical benefits to patients with advanced
squamous non-small-cell lung cancer (sq-NSCLC). This study aims to evaluate the cost …

Introduction Recently updated three-year survival data from the PACIFIC trial showed that
durvalumab consolidation therapy improved OS rates versus placebo for patients with …

Pembrolizumab monotherapy or combination therapy is an approved treatment for various
advanced non-small cell lung cancer (NSCLC) indications. We review published cost …

Purpose To evaluate the cost utility of camrelizumab plus standard chemotherapy versus
standard chemotherapy alone as a first-line treatment for advanced nonsquamous non …

Background Researchers have not simultaneously compared the cost‐effectiveness of six
immunotherapies with chemotherapy for advanced non‐small cell lung cancer. This study …

Introduction Pembrolizumab, an immune checkpoint inhibitor for treating non-small cell lung
cancer (NSCLC), can impose a high financial burden. Several studies have explored the …

Background Immunotherapies can substantially improve treatment efficacy, despite their
high cost. A comprehensive overview of the cost-effectiveness analysis (CEA) of immune …